Home › Merck Statement Regarding CUBICIN Patent Litigation
 

Keywords :   


Merck Statement Regarding CUBICIN Patent Litigation

2014-12-09 14:11:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orSteve Cragle, 908-740-1801orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement patent litigation merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Disruption as airline pilots begin industrial action
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Now is not the time for African swine fever fatigue
26.06Ex-BHS director must pay 50m over firm's collapse
26.06WEG Mexico Obtains Quality Certificate from QUALICOAT
26.06Pork producers lead coalition against sprinkler mandate
26.06Cool Roof Coatings Market to Reach US$9.2B by 2030: Fairfield
More »